

August 2015



**SUBJECT: Merck Voluntarily Discontinuing All Doses of PEGINTRON® (peginterferon alfa-2b) Vials**

Dear Pharmaceutical Purchaser:

The purpose of this communication is to inform you that, for business reasons, Merck is voluntarily discontinuing the manufacture and distribution of PEGINTRON vials in the United States, effective February 1, 2016.

Based on current inventory levels and expected demand, Merck anticipates that inventory will be exhausted in or around February 2016, though inventory of certain images may be exhausted as early as the third quarter of 2015. For your convenience, impacted NDCs are listed in the table immediately below.

Deleted Product Name / Strength	Description	NDC
PEGINTRON (peginterferon alfa-2b) for Injection, 50 mcg per 0.5 mL	A box containing one 50 mcg per 0.5 mL vial of PEGINTRON Powder for Injection and one 5 mL vial of Diluent (Sterile Water for Injection USP), 2 BD Safety Lok syringes with a safety sleeve and 2 alcohol swabs	00085-4353-01
PEGINTRON (peginterferon alfa-2b) for Injection, 80 mcg per 0.5 mL	A box containing one 80 mcg per 0.5 mL vial of PEGINTRON Powder for Injection and one 5 mL vial of Diluent (Sterile Water for Injection USP), 2 BD Safety Lok syringes with a safety sleeve and 2 alcohol swabs	00085-4354-01
PEGINTRON (peginterferon alfa-2b) for Injection, 120 mcg per 0.5 mL	A box containing one 120 mcg per 0.5 mL vial of PEGINTRON Powder for Injection and one 5 mL vial of Diluent (Sterile Water for Injection USP), 2 BD Safety Lok syringes with a safety sleeve and 2 alcohol swabs	00085-4355-01
PEGINTRON (peginterferon alfa-2b) for Injection, 150 mcg per 0.5 mL	A box containing one 150 mcg per 0.5 mL vial of PEGINTRON Powder for Injection and one 5 mL vial of Diluent (Sterile Water for Injection USP), 2 BD Safety Lok syringes with a safety sleeve and 2 alcohol swabs	00085-4356-01

Once Merck inventories are depleted, please monitor the inventory of these product images at your distribution centers to maximize service levels until all inventories are exhausted.

**Please read the Prescribing Information for PEGINTRON, including the Boxed Warning about fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders and ribavarin-associated birth defects and fetal deaths. The Medication Guide and Instructions for Use also are available.**

[Prescribing Information 1.25mL](#)

[Prescribing Information 5mL](#)



[Medication Guide](#)

[Instructions for Use 1.25mL](#)

[Instructions for Use 5mL](#)

[Instructions for Use Redipen](#)

If you have any questions, please contact your Merck Account Executive or Call the Merck Order Management Center at 800-MERCK-RX (800-637-2579), Monday through Friday, 8:00 AM to 7:00 PM, ET.

Sincerely,

A handwritten signature in black ink, appearing to read "Paul J. Bader". The signature is fluid and cursive, with a long horizontal stroke at the end.

Paul J. Bader, R.Ph.  
Director, Pharmacy & Distribution  
Merck Sharp & Dohme Corp.